EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease
Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study (SABCS 2023), which examined outcomes in patients with ESR1 mutations (ESR1m) who had been on CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy for 12 months or longer, and shares her his perspectives on how these findings may influence the use of elacestrant in ER+/HER2–- metastatic breast cancer (MBC) and impact clinical practice for community oncologists.
A post-hoc subgroup analysis of the EMERALD study (SABCS 2023) was recently published that looked at outcomes in patients with an ESR1m and who had been on a CDK4/6i + endocrine therapy for 12 months or longer by clinically relevant subgroups.
Please share your perspectives on the clinical implications of these data on the use of elacestrant for ESR1m, ER+, HER2–- MBC. Do they impact your practice? What are the key takeaways for community oncologists?
Bardia A, Cortés J, Bidard FC, et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res. 2024;30:4299-4309. https://doi.org/10.1158/1078-0432.CCR-24-1073.
